RWM
ABBV icon

RKL Wealth Management’s AbbVie ABBV Stock Holding History

RKL Wealth Management’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.7M Sell
16,991
-757
-4% -$168K 0.33% 40
2025
Q4 		$4.06M Buy
17,748
+1,328
+8% +$303K 0.33% 41
2025
Q3 		$3.8M Buy
16,420
+177
+1% +$36K 0.32% 44
2025
Q2 		$3.02M Buy
16,243
+252
+2% +$46.8K 0.27% 53
2025
Q1 		$3.35M Buy
15,991
+336
+2% +$65.3K 0.32% 48
2024
Q4 		$2.78M Buy
15,655
+244
+2% +$44.9K 0.25% 56
2024
Q3 		$3.04M Buy
15,411
+7,899
+105% +$1.47M 0.28% 50
2024
Q2 		$1.29M Buy
7,512
+203
+3% +$33.6K 0.12% 72
2024
Q1 		$1.33M Buy
7,309
+132
+2% +$22.7K 0.13% 71
2023
Q4 		$1.11M Buy
7,177
+1,494
+26% +$218K 0.12% 78
2023
Q3 		$847K Buy
5,683
+178
+3% +$26.1K 0.1% 83
2023
Q2 		$742K Buy
5,505
+63
+1% +$9.24K 0.09% 87
2023
Q1 		$867K Buy
5,442
+72
+1% +$11K 0.11% 83
2022
Q4 		$868K Buy
5,370
+17
+0.3% +$2.61K 0.12% 84
2022
Q3 		$718K Sell
5,353
-75
-1% -$10.8K 0.1% 86
2022
Q2 		$831K Buy
5,428
+158
+3% +$24.1K 0.11% 85
2022
Q1 		$854K Buy
5,270
+904
+21% +$131K 0.1% 85
2021
Q4 		$591K Sell
4,366
-1
-0% -$118 0.07% 87
2021
Q3 		$471K Sell
4,367
-2,916
-40% -$333K 0.06% 89
2021
Q2 		$820K Buy
7,283
+3,168
+77% +$357K 0.1% 82
2021
Q1 		$445K Sell
4,115
-214
-5% -$22.9K 0.06% 90
2020
Q4 		$464K Buy
4,329
+34
+0.8% +$3.27K 0.06% 91
2020
Q3 		$376K Sell
4,295
-483
-10% -$45.5K 0.06% 94
2020
Q2 		$469K Buy
4,778
+491
+11% +$43.2K 0.08% 89
2020
Q1 		$327K Sell
4,287
-1,737
-29% -$148K 0.07% 94
2019
Q4 		$533K Sell
6,024
-1,831
-23% -$152K 0.1% 91
2019
Q3 		$595K Sell
7,855
-175
-2% -$12K 0.11% 88
2019
Q2 		$584K Sell
8,030
-878
-10% -$69K 0.11% 91
2019
Q1 		$714K Buy
8,908
+542
+6% +$44.3K 0.14% 89
2018
Q4 		$771K Sell
8,366
-1,122
-12% -$98.7K 0.18% 80
2018
Q3 		$899K Sell
9,488
-1,009
-10% -$95.7K 0.19% 80
2018
Q2 		$972K Sell
10,497
-618
-6% -$60.4K 0.22% 77
2018
Q1 		$1.05M Sell
11,115
-1,852
-14% -$203K 0.25% 76
2017
Q4 		$1.25M Sell
12,967
-5,309
-29% -$500K 0.31% 67
2017
Q3 		$1.63M Sell
18,276
-1,278
-7% -$97.3K 0.46% 53
2017
Q2 		$1.42M Sell
19,554
-2,147
-10% -$144K 0.45% 51
2017
Q1 		$1.41M Sell
21,701
-3,583
-14% -$225K 0.57% 44
2016
Q4 		$1.58M Sell
25,284
-835
-3% -$51K 0.76% 35
2016
Q3 		$1.65M Buy
26,119
+3,151
+14% +$204K 0.83% 30
2016
Q2 		$1.41M Buy
22,968
+6,399
+39% +$390K 0.73% 30
2016
Q1 		$946K Buy
16,569
+5,645
+52% +$315K 0.54% 34
2015
Q4 		$647 Sell
10,924
-10,103
-48% -$582K 0.3% 34
2015
Q3 		$1.14M Sell
21,027
-3,283
-14% -$214K 0.72% 31
2015
Q2 		$1.63M Sell
24,310
-5,172
-18% -$338K 0.98% 29
2015
Q1 		$1.73M Buy
29,482
+1,733
+6% +$105K 1.04% 28
2014
Q4 		$1.82M Buy
27,749
+10,410
+60% +$656K 1.18% 28
2014
Q3 		$1M Buy
17,339
+2,899
+20% +$161K 0.7% 30
2014
Q2 		$815K Buy
14,440
+1,550
+12% +$81.3K 0.6% 31
2014
Q1 		$663K Buy
+12,890
New +$651K 0.5% 33

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RKL Wealth Management's ABBV Position: Q1 2026 in Review

RKL Wealth Management reduced its AbbVie (ABBV) stake by 4.3% in Q1 2026, selling an estimated $168K and leaving 16,991 shares worth $3.7M. The position accounts for 0.33% of the portfolio, ranked #40.

RKL Wealth Management first reported a position in ABBV in Q1 2014 and has held it in 49 quarters since. The position peaked at $4.06M in Q4 2025. 4,076 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • RKL Wealth Management held 16,991 shares of AbbVie worth $3.7M as of Q1 2026.
  • RKL Wealth Management sold 757 AbbVie shares in Q1 2026, an estimated $168K.
  • AbbVie made up 0.33% of RKL Wealth Management's portfolio in Q1 2026, its #40 holding.
  • RKL Wealth Management first reported a position in AbbVie in Q1 2014 and has held it in 49 quarters since.
  • RKL Wealth Management's AbbVie position peaked at $4.06M in Q4 2025.
  • 4,076 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on RKL Wealth Management's 13F filing for Q1 2026, filed 24 Apr 2026.